DEL_Basilea Pharmaceutica ((DEL_0QNA)), Basilea Pharmaceutica ((CH:BSLN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 study titled ‘An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections.’ The study aims to evaluate the efficacy and safety of fosmanogepix for treating invasive mold infections, a significant concern due to the rising cases of multidrug-resistant molds.
Intervention/Treatment: The study tests fosmanogepix, administered either intravenously or orally, as a treatment for invasive mold infections. The drug is intended to offer an effective alternative to standard antifungal therapies.
Study Design: This open-label, randomized study involves two cohorts. Cohort A compares fosmanogepix with standard antifungal treatments, while Cohort B administers fosmanogepix to patients who did not respond to previous treatments. The primary goal is to assess all-cause mortality by Day 42.
Study Timeline: The study began in August 2025, with primary completion expected in 2025. The last update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study’s progress could impact Basilea Pharmaceutica’s stock performance positively, as successful results may position fosmanogepix as a leading treatment for invasive mold infections. Investors should monitor competitor developments in antifungal treatments, as advancements could influence market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.